Immune globulin subcutaneous, human - klhw 20% for primary humoral immunodeficiency: an open-label, Phase III study.
Sign Up to like & getrecommendations! Published in 2019 at "Immunotherapy"
DOI: 10.2217/imt-2019-0159
Abstract: Aim: This prospective, Phase III study assessed the pharmacokinetics (PK), safety and tolerability of immune globulin subcutaneous, human - klhw 20% solution (IGSC-C 20%) in participants with primary humoral immunodeficiency (PI), compared with immune globulin… read more here.
Keywords: phase; immune globulin; phase iii; iii study ... See more keywords